Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner

Journal of Molecular and Cellular Cardiology

Volumn 69, Issue , 2014, Pages 43-51

  Ranek, Mark J ^a   Kost, Curtis K ^a   Hu, Chengjun ^a   Martin, Douglas S ^a   Wang, Xuejun ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Cardiomyocyte; Muscarinic 2 receptor; Proteasome; Protein kinase G

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; MUSCARINIC M2 RECEPTOR; PEPTIDASE; PROTEASOME; PROTEASOME SUBUNIT BETA5; PROTEASOME SUBUNIT RPT6; UBIQUITIN; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; GREEN FLUORESCENT PROTEIN; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HEART; HEART MUSCLE CELL; HEART VENTRICLE; ISOELECTRIC POINT; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; RAT; ANIMAL; CONFOCAL MICROSCOPY; CYTOLOGY; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CYCLIC GMP-DEPENDENT PROTEIN KINASES; GREEN FLUORESCENT PROTEINS; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MYOCYTES, CARDIAC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, MUSCARINIC M2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84895461701     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.01.017     Document Type: Article

References (65)

1. Castro A., Bernis C., Vigneron S., Labbe J.C., Lorca T. The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 2005, 24:314-325.
2. Goldberg A.L., Cascio P., Saric T., Rock K.L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 2002, 39:147-164.
3. Ciechanover A., Orian A., Schwartz A.L. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000, 22:442-451.
4. Haglund K., Di Fiore P.P., Dikic I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci 2003, 28:598-603.
5. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
6. Wang X., Robbins J. Heart failure and protein quality control. Circ Res 2006, 99:1315-1328.
7. Su H., Wang X. The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res 2010, 85:253-262.
8. Wang X., Su H., Ranek M.J. Protein quality control and degradation in cardiomyocytes. J Mol Cell Cardiol 2008, 45:11-27.
9. Powell S.R. The cardiac 26S proteasome: regulating the regulator. Circ Res 2006, 99:342-345.
10. Cui Z., Scruggs S.B., Gilda J.E., Gomes A.V. Regulation of cardiac proteasomes by ubiquitination, sumoylation, and beyond. J Mol Cell Cardiol 2013, 10.1016/j.yjmcc.2013.10.008.
11. Ranek M.J., Terpstra E.J.M., Li J., Kass D.A., Wang X. Protein kinase G positively regulates proteasome-mediated degradation of misfolded proteins. Circulation 2013, 128:365-376.
12. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
13. Liu J., Tang M., Mestril R., Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J Mol Cell Cardiol 2006, 40:451-454.
14. Liu J., Chen Q., Huang W., Horak K.M., Zheng H., Mestril R., et al. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J 2006, 20:362-364.
15. Wang X., Li J., Zheng H., Su H., Powell S.R. Proteasome functional insufficiency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol 2011, 301:H2207-H2219.
16. Weekes J., Morrison K., Mullen A., Wait R., Barton P., Dunn M.J. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003, 3:208-216.
17. Kostin S., Pool L., Elsasser A., Hein S., Drexler H.C., Arnon E., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003, 92:715-724.
18. Gianni D., Li A., Tesco G., McKay K.M., Moore J., Raygor K., et al. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation 2010, 121:1216-1226.
19. Predmore J.M., Wang P., Davis F., Bartolone S., Westfall M.V., Dyke D.B., et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 2010, 121:997-1004.
20. Wang X., Osinska H., Klevitsky R., Gerdes A.M., Nieman M., Lorenz J., et al. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001, 89:84-91.
21. Wang X., Osinska H., Dorn G.W., Nieman M., Lorenz J.N., Gerdes A.M., et al. Mouse model of desmin-related cardiomyopathy. Circulation 2001, 103:2402-2407.
22. Li J., Horak K.M., Su H., Sanbe A., Robbins J., Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest 2011, 121:3689-3700.
23. Li J., Powell S.R., Wang X. Enhancement of proteasome function by PA28& overexpression protects against oxidative stress. FASEB J 2011, 25:883-893.
24. Dhein S., van Koppen C.J., Brodde O.E. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001, 44:161-182.
25. Caulfield M.P. Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 1993, 58:319-379.
26. Kawano H., Okada R., Yano K. Histological study on the distribution of autonomic nerves in the human heart. Heart Vessels 2003, 18:32-39.
27. LaCroix C., Freeling J., Giles A., Wess J., Li Y.F. Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress. Am J Physiol Heart Circ Physiol 2008, 294:H810-H820.
28. Hare J.M., Keaney J.F., Balligand J.L., Loscalzo J., Smith T.W., Colucci W.S. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest 1995, 95:360-366.
29. Henning R.J., Khalil I.R., Levy M.N. Vagal stimulation attenuates sympathetic enhancement of left ventricular function. Am J Physiol 1990, 258:H1470-H1475.
30. Nagata K., Ye C., Jain M., Milstone D.S., Liao R., Mortensen R.M. Galpha(i2) but not Galpha(i3) is required for muscarinic inhibition of contractility and calcium currents in adult cardiomyocytes. Circ Res 2000, 87:903-909.
31. Dabrowska B., Dabrowski A., Skrobowski A. Parasympathetic withdrawal precedes spontaneous blood pressure elevations in women with primary hypertension. Cardiology 1996, 87:119-124.
32. Langewitz W., Ruddel H., Schachinger H. Reduced parasympathetic cardiac control in patients with hypertension at rest and under mental stress. Am Heart J 1994, 127:122-128.
33. Dall'ago P., D'Agord Schaan B., da Silva V.O., Werner J., da Silva Soares P.P., de Angelis K., et al. Parasympathetic dysfunction is associated with baroreflex and chemoreflex impairment in streptozotocin-induced diabetes in rats. Auton Neurosci 2007, 131:28-35.
34. Bunag R.D., Krizsan D., Itoh H. Diminished cardiovascular responsiveness to vagal stimulation in obese rats. Am J Physiol 1990, 259:R842-R848.
35. Girgis I., Chakko S., de Marchena E., Jara C., Diaz P., Castellanos A., et al. Effect of clonidine on heart rate variability in congestive heart failure. Am J Cardiol 1998, 82:335-337.
36. Olshansky B., Sabbah H.N., Hauptman P.J., Colucci W.S. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008, 118:863-871.
37. La Rovere M.T., Bigger J.T., Marcus F.I., Mortara A., Schwartz P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (autonomic tone and reflexes after myocardial infarction) investigators. Lancet 1998, 351:478-484.
38. Pedretti R.F., Prete G., Foreman R.D., Adamson P.B., Vanoli E. Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. J Cardiovasc Pharmacol 2003, 41:671-677.
39. Li M., Zheng C., Sato T., Kawada T., Sugimachi M., Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004, 109:120-124.
40. Zamotrinsky A.V., Kondratiev B., de Jong J.W. Vagal neurostimulation in patients with coronary artery disease. Auton Neurosci 2001, 88:109-116.
41. Gilon T., Chomsky O., Kulka R.G. Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae. EMBO J 1998, 17:2759-2766.
42. Kumarapeli A.R., Horak K.M., Glasford J.W., Li J., Chen Q., Liu J., et al. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J 2005, 19:2051-2053.
43. Dong X., Liu J., Zheng H., Glasford J.W., Huang W., Chen Q.H., et al. In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes. Am J Physiol Heart Circ Physiol 2004, 287:H1417-H1425.
44. Kumarapeli A.R., Su H., Huang W., Tang M., Zheng H., Horak K.M., et al. Alpha B-crystallin suppresses pressure overload cardiac hypertrophy. Circ Res 2008, 103:1473-1482.
45. Tydlacka S., Wang C.E., Wang X., Li S., Li X.J. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 2008, 28:13285-13295.
46. Su H., Li J., Menon S., Liu J., Kumarapeli A.R., Wei N., et al. Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice. Circ Res 2011, 108:40-50.
47. Kagawa T., Watanabe N., Mochizuki K., Numari A., Ikeno Y., Itoh J., et al. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol 2008, 294:G58-G67.
48. Su H., Li F., Ranek M.J., Wei N., Wang X. COP9 signalosome regulates autophagosome maturation. Circulation 2011, 124:2117-2128.
49. Brodde O.E., Bruck H., Leineweber K., Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 2001, 96:528-538.
50. Deguchi A., Soh J.W., Li H., Pamukcu R., Thompson W.J., Weinstein I.B. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther 2002, 1:803-809.
51. Moens A.L., Takimoto E., Tocchetti C.G., Chakir K., Bedja D., Cormaci G., et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117:2626-2636.
52. Hidaka H., Kobayashi R. Pharmacology of protein kinase inhibitors. Annu Rev Pharmacol Toxicol 1992, 32:377-397.
53. Porter T.R., Eckberg D.L., Fritsch J.M., Rea R.F., Beightol L.A., Schmedtje J.F., et al. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest 1990, 85:1362-1371.
54. Azevedo E.R., Parker J.D. Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 1999, 100:274-279.
55. Scruggs S.B., Zong N.C., Wang D., Stefani E., Ping P. Post-translational modification of cardiac proteasomes: functional delineation enabled by proteomics. Am J Physiol Heart Circ Physiol 2012, 303:H9-H18.
56. Asai M., Tsukamoto O., Minamino T., Asanuma H., Fujita M., Asano Y., et al. PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J Mol Cell Cardiol 2009, 46:452-462.
57. Lu H., Zong C., Wang Y., Young G.W., Deng N., Souda P., et al. Revealing the dynamics of the 20S proteasome phosphoproteome: a combined CID and electron transfer dissociation approach. Mol Cell Proteomics 2008, 7:2073-2089.
58. Zhang F., Hu Y., Huang P., Toleman C.A., Paterson A.J., Kudlow J.E. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 2007, 282:22460-22471.
59. Divald A., Kivity S., Wang P., Hochhauser E., Roberts B., Teichberg S., et al. Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 2010, 106:1829-1838.
60. Churchill E.N., Ferreira J.C., Brum P.C., Szweda L.I., Mochly-Rosen D. Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion. Cardiovasc Res 2010, 85:385-394.
61. Chatterjee P.K., Yeboah M.M., Dowling O., Xue X., Powell S.R., Al-Abed Y., et al. Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity. PLoS One 2012, 7:e35361.
62. Li J., Powell S.R., Wang X. Enhancement of proteasome function by PA28& overexpression protects against oxidative stress. FASEB J 2011, 25:883-893.
63. Chen Q., Liu J.B., Horak K.M., Zheng H., Kumarapeli A.R., Li J., et al. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 2005, 97:1018-1026.
64. Zong C., Gomes A.V., Drews O., Li X., Young G.W., Berhane B., et al. Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ Res 2006, 99:372-380.
65. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.